Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 9/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3203094 | 0.85 | AKR1B1 (0.39) | FFAR1CYP2C9 | |
| SCHEMBL3216034 | 0.81 | MAOB (0.33) | FFAR1USP2CYP2C9CYP2B6SLCO1B3 | |
| SCHEMBL17363934 | 0.79 | NR3C1 (0.42) | FFAR1CYP2C9CYP2B6SLCO1B3 | |
| SCHEMBL17363890 | 0.79 | NR3C1 (0.42) | FFAR1CYP2C9CYP2B6SLCO1B3 | |
| SCHEMBL17363948 | 0.79 | NR3C1 (0.42) | FFAR1CYP2C9CYP2B6SLCO1B3 | |
| SCHEMBL20804518 | 0.78 | AR (0.40) | SMN1; SMN2 | |
| SCHEMBL3214130 | 0.78 | TRPM5 (0.37) | — | |
| SCHEMBL19776291 | 0.75 | FFAR1 (0.54) | FFAR1CYP2C9CYP2B6SLCO1B3 | |
| SCHEMBL19776202 | 0.75 | FFAR1 (0.54) | FFAR1CYP2C9CYP2B6SLCO1B3 | |
| SCHEMBL5530352 | 0.75 | NLRP3 (0.35) | CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035871-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | WYETH | 2010-02-11 | — | — | US | disclosed |
| WO-2008052075-A2 | BENZOXAZINE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035871-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | HTR2C, HTR5A, NPY1R | FFAR1 279/4885USP2 3883/4885HPGD 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.